



The Nifty previous session ended 1.11% up at 11,022.20. It opened on a positive note and continued trading on positive towards finishing off above 10,980. Finishing off above 10,980 implies- soon it may challenge next resistance placed around 11,100 levels. Higher resistance is placed around 11,180.

On the Nifty hourly chart; RSI is again approaching towards overbought zone, however, considering the broader uptrend it may again find support around 10,800 levels in case of intraday retracement.

Nifty patterns on multiple time frames suggest; it finished off above 10,980, which brightens the possibility of further rise towards 11,100 levels.

Nifty Crucial Supports & Resistances-
Supports- 10800, 10760 Resistances- 11100, 11180

Open positional calls-

T+15 Investment Buy-
|Cash Segment| Accumulate DCB on dips around @ 82-80, TGT- 100, SL- closing below 70

T+7 Positional Sell-
|Futures Segment| LUPIN Fut @ 882-885, TGT- 825, SL- above 915

T+7 Positional Sell-
|Futures Segment| TATA STEEL Fut @ 337-339, TGT- 309, SL- above 354

T+7 Positional Sell-
|Futures Segment| BEL Fut @ 101-102, TGT- 92, SL- above 107

T+15 Positional Buy-
|Cash Segment| Accumulate GLENMARK (CMP- 430.00) on dips around @ 425-420, TGT- 480, SL - closing below 390

T+3 Positional Buy-
|Cash Segment| SIEMENS on dips around @ 1180-1175, TGT- 1225, SL- closing below 1150

T+1 Positional Buy-
|Cash Segment| UJJIVAN on dips around @ 253-252, TGT- 260, SL- closing below 248

Key Contents	Page No.
Result Analysis	4
Domestic News	5

Nifty Intraday Chart



Market in Retrospect

Indian equity markets held on to opening gains to end higher for the fourth straight day, outperforming their global peers.

The NSE Nifty 50 index ended at 11,022, up 1.1%. The broader markets represented by the NIFTY 500 Index ended 1.01% higher, ending at 8985.10. NIFTY IT was the top gainer, gaining by 2.60%, followed by NIFTY Finance gaining by 1.63%. NIFTY Pharma was the top loser, losing by 1.60%.

Britannia was the top gainer, gaining by 5.22%, followed by Bajaj Finance and HCL Technologies, which gained by 4.25% & 4.08% respectively. Sun Pharma was the top loser, losing by 3.93%, followed by Cipla and Zee Enterprises, which fell by 2.14% & 1.68% respectively.

The Advance: Decline ratio stood at 1139:783

Market Turnover (In Crore) 20-07-2020

Name	Last	Previous
NSE Cash	56333.16	58666.88
NSE F&O	1187373.11	1075163.07
BSE Cash	3,735.31	3,346.41
BSE F&O	18.69	197.27

FII Derivatives Flow (In Crore) 20-07-2020

Instrument	Purchase	Sale	Net
Index Future	4151.75	4219.86	-68.11
Index Option	189941.86	190240.88	-299.02
Stock Future	14904.96	15179.98	-275.02
Stock Option	4591.02	4613.13	-22.11

Institutional Flow (In Crore) 20-07-2020

Institution	Purchase	Sale	Net
FII	4960.3	3250.33	1709.97
DII	3306.19	4828.18	1521.99

NIFTY Top Gainers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
Britannia	5.22	4.89	3785159	1500939
Bajaj Finance	4.25	6.40	10556334	10989380
HCL Technologies	4.08	7.63	10543170	13837340
Bajaj Finserv	4.06	2.46	1221890	864260
UPL	3.94	3.29	9435359	3772521

NIFTY Top Losers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
NTPC	1.30	3.06	12349625	13146090
BPCL	1.46	15.09	14373074	16387010
Zee Enterprise	1.68	10.94	16710722	18067310
Cipla	2.14	5.64	5469496	8895872
Sun Pharmaceutical	3.93	3.18	16111403	8013619

Bulk and Block Deals

<https://www.nseindia.com/products/content/equities/equities/bulk.htm>
<http://www.bseindia.com/markets/equity/EQReports/BulknBlockDeals.aspx>

*Data not updated till 6:25PM

Sensex Intraday Chart



Market in Detailed (Updated after 4:00 PM)

Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	37418.99	398.85	1.08	1.98	7.74	18.23	2.39
Nifty	11022.20	120.50	1.11	2.03	7.59	19.01	3.48
BSE M Cap	13654.26	123.51	0.91	1.87	6.64	15.73	3.01
BSE S Cap	12915.27	132.74	1.04	1.03	5.20	18.63	2.97
Nifty MC 100	15388.55	146.25	0.96	1.13	5.65	17.35	6.34
BSE Auto	16239.75	78.22	0.48	1.18	8.23	28.03	0.13
BSE Capgoods	12900.53	16.71	0.13	0.94	2.68	4.92	28.44
BSE FMCG	11659.73	42.79	0.37	1.15	8.42	8.11	5.16
BSE Metal	7635.18	6.48	0.08	0.04	5.63	20.16	25.44
BSE Oil&Gas	13325.16	34.68	0.26	3.04	3.39	17.44	4.18
BSE Healthcare	17010.25	113.61	0.66	2.14	4.95	14.14	33.18
BSE Power	1514.89	3.10	0.20	2.87	1.94	0.27	24.40
BSE Realty	1552.71	5.12	0.33	2.66	5.64	6.69	27.48
BSE ConsDur	21328.28	245.93	1.17	3.56	4.59	4.67	6.98
BSE Bank	25216.87	343.23	1.38	0.89	4.02	7.66	24.64
BSE IT	17437.74	391.52	2.30	9.01	19.93	34.25	12.83

Bond Markets

Name	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	0.62	0.01	1.56	0.26	11.09	1.90	69.99
UK	0.16	0.00	0.61	11.83	31.09	51.34	77.66
Brazil	4.71	0.04	0.90	2.75	3.21	11.90	3.83
Japan	0.03	0.01	29.17	22.50	72.22	40.91	123.49
Australia	0.89	0.02	2.30	1.44	3.02	6.22	34.37
India	5.80	0.01	0.10	0.24	0.89	6.60	8.88
Switzerland	0.43	0.00	0.92	6.97	6.97	2.05	30.20
Germany	0.44	0.01	2.01	5.04	5.54	2.23	35.19

Currency

Name	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	74.92	0.10	0.14	0.37	1.48	2.18	8.00
USD Index	95.80	0.14	0.15	0.69	1.87	4.16	1.39
YUAN	6.99	0.00	0.05	0.13	1.14	1.21	1.54
GBP	1.26	0.00	0.26	0.37	1.06	1.28	1.00
EUR	1.15	0.00	0.20	0.94	1.69	5.42	2.16
YEN	107.17	0.15	0.14	0.11	0.24	0.42	0.65

Freight

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	1710.00	11.00	0.65	5.52	9.97	125.89	21.20
Baltic Dirty	520.00	11.00	2.16	4.21	2.16	56.01	16.40
SG Dubai HY	0.51	0.23	82.14	13.33	142.86	80.38	92.41

Global Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	26671.95	62.76	0.23	2.29	3.09	12.78	1.78
Nasdaq	10503.19	29.36	0.28	1.08	5.60	22.69	28.93
S&P 500	3224.73	9.16	0.28	1.25	4.10	14.22	8.34
FTSE100	6244.39	46.27	0.74	1.10	0.77	7.42	16.84
CAC40	5054.48	15.12	0.30	0.04	1.50	11.62	8.97
DAX	12954.70	35.30	0.27	1.21	5.06	21.35	5.67
Mexico IPC	36327.84	137.83	0.38	0.38	5.41	5.37	12.69
Brazil Bovespa	102888.3	2335.00	2.32	2.86	6.54	30.28	0.54
Russian RTS	1225.04	8.86	0.73	0.77	1.97	14.67	9.30
Japan Nikkei	22717.48	21.06	0.09	0.30	1.06	15.50	5.83
Hang Seng	25057.99	31.18	0.12	2.77	1.68	2.99	12.89
Taiwan Index	12174.54	7.02	0.06	0.30	5.41	15.00	11.97
Shanghai Comp	3314.15	100.02	3.11	3.75	11.68	16.18	13.34
KOSPI	2198.20	2.99	0.14	0.56	2.66	15.79	4.96
Malaysia KLCI	1589.45	6.88	0.43	1.06	5.45	12.48	4.15
Jakarta Comp	5051.11	28.48	0.56	0.26	2.20	10.38	21.77
Philippine SE	6150.70	61.95	1.02	0.35	2.60	7.27	25.63
Thai Exch	1358.29	1.29	0.09	1.19	0.91	7.26	21.72

Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	40.22	0.37	0.91	0.30	1.18	206.88	27.70
BRENT Crude	42.75	0.39	0.90	0.07	1.45	28.26	29.08
Natural Gas	1.71	0.01	0.81	2.01	2.52	26.30	30.28

LME

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1811.06	0.54	0.03	0.45	3.85	6.80	27.05
Silver(\$/Ounce)	19.44	0.10	0.53	1.86	10.25	26.86	19.95
Aluminium	1626.00	9.25	0.57	1.99	2.73	10.65	11.12
Copper	6456.00	18.25	0.28	0.58	12.45	24.30	8.18
Zinc	2173.00	43.25	1.95	0.48	8.08	11.52	12.20
Lead	1793.50	37.50	2.05	2.63	0.45	8.48	10.30

Agro Commodities

Name	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	101.55	0.75	0.73	2.94	5.89	12.83	16.11
Cotton	62.08	0.14	0.23	2.00	3.80	10.21	5.55
Sugar	11.69	0.04	0.34	0.95	4.02	11.02	10.76
Wheat	531.25	3.50	0.65	1.24	9.48	3.67	1.25
Soybean	899.25	4.25	0.47	2.74	2.10	6.33	5.86

ACC

ACC reported a 40.61 per cent year-on-year (YoY) drop in standalone net profit at INR267.99 crore for the quarter ended June 30. It had reported a net profit of INR451.30 crore in the corresponding quarter last year. Standalone revenue of the company decreased 37.31 per cent YoY to INR2,600.83 crore in Q1FY21, over INR4,149.72 crore in the same period last year. The margin of the company stood at 20.13 per cent for the second quarter. On a consolidated basis, the net profit of the company dropped to INR270.95 crore from INR455.68 crore in the corresponding quarter last year.

Swaraj Engines

Net profit of Swaraj Engines declined 53.66% to INR7.84 crore in the quarter ended June 2020 as against INR16.92 crore during the previous quarter ended June 2019. Sales declined 43.04% to INR116.99 crore in the quarter ended June 2020 as against INR205.38 crore during the previous quarter ended June 2019.

SBI Card

SBI Card posted 13.80 per cent year-on-year (YoY) rise in net profit at INR393.29 crore for the quarter ended June 30. It had posted a net profit of INR345.59 crore in the corresponding quarter last year. Total revenue from operation increased 4 per cent YoY to INR2,152.20 crore during the quarter under review against INR2,068.28 crore in the corresponding quarter last year. The company posted nearly 28 per cent drop in total expenditure at INR134.98 crore in Q1FY21, over INR186.94 crore in Q1FY20.

Steel Strips Wheels bags fresh orders worth about INR11.25 crore for US caravan trailer market

Auto component maker Steel Strips Wheels has received orders worth USD 1.5 million (about INR11.25 crore) for over 1.45 lakh wheels for the US caravan trailer market. To be executed in the month of September with a value of over USD 1.5 million, from its Chennai plant. With this, the company's order wins for this month stand at over INR21 crore. With this, the company's order wins for this month stand at over INR21 crore. Recurring inflow of similar orders are expected in months to come. With this order our Chennai plant will aim to run its passenger car wheel business at its highest monthly run rate. Last week, SSWL had received orders worth 1,78,000 euros (INR1.51 crore) from the European Union and the US. The company also secured orders worth USD 1,40,000 (around INR1.05 crore) along with maiden order for alloy wheels from the EU market. Earlier this month, it had bagged orders worth USD 1 million (about INR7.5 crore) for over 1.19 lakh wheels for the US caravan trailer market.

Muthoot Finance expects gold loan portfolio to grow 15-20% in 2020-21

Muthoot Finance NSE 2.23 % expects its gold loan business to grow 15-20 per cent during the current financial year, and hopes the gold portfolio to remain largely unaffected by the coronavirus pandemic. As gold prices are currently ruling high, the collateral is becoming more valuable, he said adding that now, people can borrow more money out of the same holding and as a lot of publicity is going around gold and gold prices, more and more people are inclined to take gold loan. Muthoot Finance witnessed a 22 per cent growth in its gold loan portfolio in the last financial year ended March 2020. Last year Muthoot Finance grew by 22 per cent in gold loan. This year also, we have given a guidance that we will grow our gold loan business AUM by 15-20 per cent in 2020-21.

Cement demand to fall by 22-25% in FY 2021, prices to remain stable

Amid the prolonged nationwide lockdown and subsequent state and city specific restrictions disrupting construction activities, cement demand to de-grow by 22%-25% in FY2021. The demand is likely to recover only from the second half of FY2021, post monsoons It should be noted that the rural segment has been relatively less impacted by the pandemic. As per estimates, housing, including the affordable housing segment, accounts for around 65%-70% of the cement demand followed by infrastructure segment at 20%-23%, and commercial and industrial capex at 10%. While rural housing is likely to drive the demand in the current fiscal, the urban housing, infrastructure and commercial and industrial capex are likely to take a back seat.

Over 158 applications for generic products pending with USFDA for approval

Drug firm Lupin remains bullish over its US business with over 158 applications for generic products pending with the US drug regulator for approval, as per the company's annual report for 2019-20. Lupin now have over 158 abbreviated new drug applications (ANDAs) pending approval with the US Food and Drug Administration (USFDA), a rich pipeline addressing a total market of over USD 71.7 billion comprising of inhalation, first-to-files and injectable product. During the year, the company filed 21 ANDAs, two of which were confirmed exclusive first-to-files. Lupin expect to continue our ramp-up of Levothyroxine and look forward to the launch of our first major inhalation product, Albuterol in the coming fiscal. During 2019-20, the US business contributed 38 per cent to the company's revenues, aggregating USD 800 million (about INR6,000 crore), a 3 per cent growth over 2018-19.

CORPORATE ACTION BONUS / RIGHTS / STOCK SPLIT / DIVIDEND / FCCB / M&A / WARRANTS ETC.

Company	Details
HIL Ltd	Cash dividend of INR10 effective 21-07-20
Vaibhav Global Ltd	Cash dividend of INR7 effective 21-07-20

Domestic Events

- **Upcoming Result:-** Axis Bank, Bajaj Finance, Bajaj Finserv, DCM Shriram, Hatsun Agro Product, HDFC Life Insurance, Himadri Speciality Chemical, Hindustan Copper, HUL, Hindustan Zinc, ICICI Prudential Life Insurance, Mahindra CIE, SBI Life Insurance, Shanthi Gears, SML Isuzu, Surat Textile Mills, Syngene International, Tata Elxsi

Global Events

- Japan Inflation for June 2020.

Analyst Certification:

We /I, Deepankar Saha & Jaydeb Dey Research Analyst(s) of SMIFS Limited (in short “SMIFS / the Company”), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

Terms & Conditions and Other Disclosures:

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation or act as a market maker in the Financial Instruments of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report. Or at the time of Public Appearance. SMIFS does not have proprietary trades but may at a future date, may opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/ short position in the above Scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing. The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

Neither the Research Analysts nor SMIFS have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at www.nseindia.com and/or www.bseindia.com, www.mcxindia.com and/or www.icex.com.

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

For queries related to compliance of the report, please contact: -

Sudipto Datta, Compliance Officer

SMIFS Limited.

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5414 /91 33 6634 5414

Email Id.: compliance@smifs.com

Website: www.smifs.com